Posted by Craig, September 2017

Harnessing Clinical Insights from Tumor Models Boston 2017

Tumor Models Boston 2017

The 5th Annual Tumour Models Boston event aimed to showcase the latest advancements in the application of preclinical models to enhance the translation of cancer therapies from animal to patient! It was clear two of the showcases really stood out for Fiona, as I interviewed her on Skype from ECCB in Prague.

Horizon launches new model

During their track ['Highly Characterized Patient-Derived Xenograft Collections for Preclinical Studies'http://tumor-models.com/wp-content/uploads/sites/67/2017/07/Jochen-Hartner.pdf), Jochen Hartner (Director, Scientific Liaison, Field Application Leader) from Horizon Discovery showcased the company's impressive model collection. Their presentation includes more information on their genetically engineered models, CDX models, PDX models, PDX Models (humanized immune system) and syngeneic models. With an in-depth summary of their Breast Cancer PDX model collection (WHIMs), Wistar Melanoma PDX model Collection and X-MAN Isogenic and CCLE Derived Cell Lines for Xenograft studies (CDX), it was an excellent overview of the data which will be hitting our platform in the near future.

Envigo launches new model

But the new models didn't stop there! Lee Coney, Chief Scientific Officer for Envigo also showcased their new model to event participants during his talk 'Characterization & Application of the Triple Immunodeficient R2G2 (Rag2/Il2rg Double Knockout) Mouse' During his presentation, Lee gave an overview on the new R2G2 model, comparative analysis of the R2G2 and NSGTM immune systems and the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models and the impact of radiosensitivity on experimental design.

For more information visit the Envigo website.

Envigo are also offering a free sampling program for the model (restrictions apply), find out more here.

Champions Oncology TumorGraft database

Possibly the most interesting for me, and our development team, was Neal Goodwin's presentation Advanced PDX Tumor Biology Platforms for Drug Advancement.

The first thing to really catch my eye was a graph on slide 6 detailing the **'large cohorts of clinically-relevant TumorGraft models' It listed the types of tumor models offered by Champions Oncology and provided a very simple keyword breakdown. The sort of keywords our users would use to find a PDX model on the new PDX discover platform. Even the colour coding struck me as a level of UX/UI already visible on the discover platform with filters on assay types. It was easy to see how their data would look visually on the platform and how we could use keywords such as 'Tissue' to help users find the models they need.

Page 8 could not have been more appropriate to the PDX consortium, with Champions detailing the Tumor Graft database. Champions have developed the interface to allow a user to query by molecular annotations, clinical data, patient treatment history and SoC screens in TumorGraft and then select, and the most relevant models such as histology, growth curves and tissue microarrays.

Champions Oncology database, with comprehensive annotations, allows a user to compare cohorts of well-characterised models, build complex queries, save search results for future use and export data. Now, imagine that functionality, but across every PDX vendor in the world... if you can, then you begin to see the Repositive and AstraZeneca vision for the PDX platform.

The PDX Consortium

It is unsurprising that the generation of new models caught the attention of Fiona. After meeting with existing and potential new members of our PDX Consortium with AstraZeneca in Boston, Fiona has been looking at the data requirements of both PDX vendor and PDX data consumer. PDX data has different associated metadata and there is need for data consumers to pre-qualify the characteristics of models before they purchase them. Understanding the future models which will be indexed on the platform, helps us prepare and make this data visible to the scientific community, from day one.

The consortium promises numerous benefits to PDX users and PDX vendors. All partners have the opportunity to influence the design of the product from its inception to meet their specific needs.

For more information visit www.repositive.io/pdx or email <a href='pdx@repositive.io'pdx@repositive.io</a>

Related Content

Mouse Trap: How to win in the PDX game

Repositive Launches Consortium with AstraZeneca to Improve Oncology Research

Repositive and AstraZeneca Announce Initial Members of PDX Consortium

Find the right PDX model for your research

Breast Friends: Best Friends who beat Breast Cancer

Posted by
Craig Smith

Craig Smith

Marketing Manager
See all Craig's posts